


# BLADMIR TIMES



## AIM OF THE STUDY

To evaluate the treatment satisfaction and therapeutic efficacy of mirabegron in patients with overactive bladder (OAB) who were unsatisfied with previous antimuscarinic therapy



## METHODOLOGY



### Study design

- A multicenter, open-label, single-arm, prospective study



### Study participants & treatment

- Patients diagnosed with OAB and treated with antimuscarinics within two years of screening and showing dissatisfaction over poor efficacy or adverse effects of antimuscarinic
- A total of 397 patients received mirabegron 50 mg once daily for 12 weeks



### Outcome variables

- **Primary end-point:** Percentage of patients reporting treatment satisfaction questions (TSQ) at week 12 ("very satisfied" or "somewhat satisfied")
- **Secondary end-points:** Percentage of patients reporting treatment satisfaction at week 4, mean changes from baseline at weeks 4 and 12 in the number of micturitions, urgency episodes, and urgency urinary incontinence episodes per 24 h




## RESULTS


- According to the TSQ, 71.3% of patients were "somewhat dissatisfied" with their previous antimuscarinic use, while 28.7% were "very dissatisfied." The response rate of treatment satisfaction on the TSQ after treating with mirabegron was 62.6% at 4 weeks and raised to 69.3% at 12 weeks (Figure 1)
- The proportion of patients who were "very satisfied" increased from 14.1% at 4 weeks to 21.9% at 12 weeks (Figure 1)
- The number of micturitions per 24 hours, urgency urinary incontinence per 24 hours, and urgency episodes per 24 hours improved significantly from baseline to week 12 (Figure 2)
- In the poor efficacy group, treatment satisfaction increased significantly from 60.7% at 4 weeks to 69.1% at 12 weeks
- Both overactive bladder questionnaire short form (OAB-q-SF) and overactive bladder symptom score (OABSS) were significantly upgraded in comparison to the baseline scores

- At 4 and 12 weeks, 27.5% and 41.8% of patients, respectively, responded to the global response assessment (GRA) as being moderately or markedly improved
- At 12 weeks, 80.8% of patients were willing to continue mirabegron.

**Figure 1: Satisfaction rates with treatments**



**Figure 2: Change in the number of micturitions, urgency and urinary incontinence episodes per 24 hours from baseline to week 12**



## CLINICAL IMPLICATIONS

**Mirabegron is well-tolerated and improves treatment satisfaction and OAB symptoms in individuals with OAB who are dissatisfied with previous antimuscarinic treatments, regardless of the cause of dissatisfaction.**

# In OAB Management

In patients with

- Severe OAB symptoms
- Inadequate response to Solifenacin monotherapy

**BILAYERED TABLET**

Rx **BLADMIR-S<sup>®</sup>**

Mirabegron (ER) 25mg/50mg and Solifenacin Succinate 5mg tablets

Dual Action for Bladder Control

In,

- OAB patients for long term maintenance therapy
- Patients with Discontinued Anti-Muscarinic therapy

Rx **BLADMIR<sup>™</sup>**

Mirabegron extended release tablets 25mg/50mg

Better Control...Better Quality of Life

